We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 03. | 장 마감 후 (AMC) | $-0.4 | — | — | $86.26M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.9 | — | — | $87.99M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $0.3 | — | — | $245.76M |
Consensus PT $45.88 · 8 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 13. | BTIG | — | 의견 유지 | Buy → Buy | — | BTIG: Buy |
| 2026. 05. 07. | Baird | — | 의견 유지 | Outperform → Outperform | — | Baird: Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $0.22 | — | — | $159.98M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 248,840 | $6.11B | 0.01% | — | 신규 편입 |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 119,458 | $4.65B | 0.01% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Stored first · Google News · Yahoo Finance (English)
Maetzold-related trusts sell shares (CSTL) in multiple Form 144 trades - Stock Titan
Maetzold-related trusts sell shares (CSTL) in multiple Form 144 trades Stock Titan
Castle Biosciences (CSTL) director receives 11,766 RSUs in new equity grant - Stock Titan
Castle Biosciences (CSTL) director receives 11,766 RSUs in new equity grant Stock Titan
Director at Castle Biosciences (CSTL) awarded 11,766 restricted stock units - Stock Titan
Director at Castle Biosciences (CSTL) awarded 11,766 restricted stock units Stock Titan
Director at Castle Biosciences (CSTL) awarded 11,766 restricted stock units - Stock Titan
Director at Castle Biosciences (CSTL) awarded 11,766 restricted stock units Stock Titan
Director at Castle Biosciences (CSTL) granted 11,766 RSUs - Stock Titan
Director at Castle Biosciences (CSTL) granted 11,766 RSUs Stock Titan
Castle Biosciences (CSTL) director receives 11,766 RSU compensation award - Stock Titan
Castle Biosciences (CSTL) director receives 11,766 RSU compensation award Stock Titan